

Serial No.: 10/594,293
Group Art Unit No.: 1643

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (Cancelled)

3. (Currently Amended) A therapeutic antibody that specifically binds to OSM, and modulates the interaction between OSM and gp130~~The antibody of claim 2 further comprising~~[[:]]:

CDRH1 of SEQ.I.D.NO: 1₁

CDRH2 of SEQ.I.D.NO: 2₁

CDRH3 of SEQ.I.D.NO: 3₁

CDRL1 of SEQ.I.D.NO: 4₁

CDRL2 of SEQ.I.D.NO: 5₁ and

CDRL3 of SEQ.I.D.NO: 6₁

4. (Cancelled)

5. (Currently Amended) A therapeutic antibody that specifically binds to OSM, and modulates the interaction between OSM and gp130~~The Antibody of claim 4 further comprising~~[[:]]:

CDRH1 of SEQ.I.D.NO: 40₁

CDRH2 of SEQ.I.D.NO: 41₁

CDRH3 of SEQ.I.D.NO: 42₁

CDRL1 of SEQ.I.D.NO: 43₁

CDRL2 of SEQ.I.D.NO: 44₁ and

CDRL3 of SEQ.I.D.NO: 45₁

6-13. (Cancelled)

Serial No.: 10/594,293
Group Art Unit No.: 1643

14. (Currently Amended) The[[A]] humanised therapeutic antibody of claim [[1]]3, which specifically binds hOSM and modulates the interaction between hOSM and gp130 comprising a V_H domain of SEQ.I.D.NO: 9 and a V_L domain of SEQ.I.D.NO: 10.

15. (Currently Amended) The[[A]] humanised therapeutic antibody of claim [[1]]3, which specifically binds hOSM and modulates the interaction between hOSM and gp130 comprising a heavy chain of SEQ.I.D.NO: 11 and a light chain of SEQ.I.D.NO: 12.

16. (Currently Amended) The[[A]] humanised therapeutic antibody of claim [[1]]5 which specifically binds hOSM and modulates the interaction between hOSM and gp130 comprising a V_H domain of SEQ.I.D.NO: 48 and a V_L domain of SEQ.I.D.NO: 49

17. (Currently Amended) The[[A]] humanised therapeutic antibody of claim [[1]]5 which specifically binds hOSM and modulates the interaction between hOSM and gp130 comprising a heavy chain of SEQ.I.D.NO: 50 and a light chain of SEQ.I.D.NO: 51.

18-78. (Cancelled)